Gerbaud Edouard, Bouchard de La Poterie Ambroise, Baudinet Thomas, Montaudon Michel, Beauvieux Marie-Christine, Lemaître Anne-Iris, Cetran Laura, Seguy Benjamin, Picard François, Vélayoudom Fritz-Line, Ouattara Alexandre, Kabore Rémi, Coste Pierre, Domingues-Dos-Santos Pierre, Catargi Bogdan
Cardiology Intensive Care Unit and Interventional Cardiology, Hôpital Cardiologique du Haut-Lévêque, 33604 Pessac, France.
Bordeaux Cardio-Thoracic Research Centre, U1045, Bordeaux University, 33076 Bordeaux, France.
J Clin Med. 2022 Mar 11;11(6):1549. doi: 10.3390/jcm11061549.
(1) Background: Hyperglycaemia and hypoglycaemia are both emerging risk factors for cardiovascular disease. Nevertheless, the potential effect of glycaemic variability (GV) on mid-term major cardiovascular events (MACE) in diabetic patients presenting with acute heart failure (AHF) remains unclear. This study investigates the prognostic value of GV in diabetic patients presenting with acute heart failure (AHF). (2) Methods: this was an observational study including consecutive patients with diabetes and AHF between January 2015 and November 2016. GV was calculated using standard deviation of glycaemia values during initial hospitalisation in the intensive cardiac care unit. MACE, including recurrent AHF, new-onset myocardial infarction, ischaemic stroke and cardiac death, were recorded. The predictive effects of GV on patient outcomes were analysed with respect to baseline characteristics and cardiac status. (3) Results: In total, 392 patients with diabetes and AHF were enrolled. During follow-up (median (interquartile range) 29 (6−51) months), MACE occurred in 227 patients (57.9%). In total, 92 patients died of cardiac causes (23.5%), 107 were hospitalised for heart failure (27.3%), 19 had new-onset myocardial infarction (4.8%) and 9 (2.3%) had an ischaemic stroke. Multivariable logistic regression analysis showed that GV > 50 mg/dL (2.70 mmol/L), age > 75 years, reduced left ventricular ejection fraction (LVEF < 30%) and female gender were independent predictors of MACE: hazard ratios (HR) of 3.16 (2.25−4.43; p < 0.001), 1.54 (1.14−2.08; p = 0.005), 1.47 (1.06−2.07; p = 0.02) and 1.43 (1.05−1.94; p = 0.03), respectively. (4) Conclusions: among other well-known factors of HF, a GV cut-off value of >50 mg/dL was the strongest independent predictive factor for mid-term MACE in patients with diabetes and AHF.
(1)背景:高血糖和低血糖都是心血管疾病新出现的危险因素。然而,血糖变异性(GV)对急性心力衰竭(AHF)糖尿病患者中期主要心血管事件(MACE)的潜在影响仍不清楚。本研究调查了GV在急性心力衰竭(AHF)糖尿病患者中的预后价值。(2)方法:这是一项观察性研究,纳入了2015年1月至2016年11月期间连续的糖尿病合并AHF患者。GV通过重症监护病房初始住院期间血糖值的标准差来计算。记录MACE,包括复发性AHF、新发心肌梗死、缺血性卒中和心源性死亡。分析GV对患者预后的预测作用,并考虑基线特征和心脏状况。(3)结果:共纳入392例糖尿病合并AHF患者。在随访期间(中位数(四分位间距)为29(6 - 51)个月),227例患者(57.9%)发生了MACE。共有92例患者死于心脏原因(23.5%),107例因心力衰竭住院(27.3%),19例发生新发心肌梗死(4.8%),9例发生缺血性卒中(2.3%)。多变量逻辑回归分析显示,GV>50 mg/dL(2.70 mmol/L)、年龄>75岁、左心室射血分数降低(LVEF<30%)和女性是MACE的独立预测因素:风险比(HR)分别为3.16(2.25 - 4.43;p<0.001)、1.54(1.14 - 2.08;p = 0.005)、1.47(1.06 - 2.07;p = 0.02)和1.43(1.05 - 1.94;p = 0.03)。(4)结论:在心力衰竭的其他已知因素中,GV临界值>50 mg/dL是糖尿病合并AHF患者中期MACE最强的独立预测因素。